0
     

Report Added
Report already added
Therapeutics for Women's Health: Technologies and Global Markets

Therapeutics for Women's Health: Technologies and Global Markets

Report Scope:

This report is an analytical business tool that comprehensively evaluates the global market for women’s health therapeutics. The format of the study is organized around the following topics -
- Detailed study around women’s diseases, such as endometriosis, postmenopausal osteoporosis, menopause, breast cancer and PCOS.
- Disease incidence and prevalence.
- Regulatory structure of pharmaceutical industry.
- Market characterization, unmet need, market size and segmentation.
- Market drivers and restraints.
- Detailed market projections through 2026.
- Competition and market shares.
- Pricing and reimbursement.
- Marketed and pipeline (R&D) products along with description, regulatory status, and clinical trials.
- Observations and conclusions regarding the future of market for women’s health therapeutics.
- Profiles of market participants and associations.

Report Includes:

- 58 data tables and 56 additional tables
- An overview of the global market and technologies for women's health therapeutics
- Estimation of the market size and analyses of global market trends, with data from 2018, 2019, 2020, estimates for 2021 and projections of compound annual growth rates (CAGRs) through 2026
- Detailed study around women’s diseases such as endometriosis, postmenopausal osteoporosis, menopause, breast cancer and polycystic ovary syndrome (PCOS); their historical background, stages, symptoms, risk factors and genetic factors, diagnosis, and treatment, etiology, pathophysiology, epidemiology, and economic burden
- Discussion on aging and women’s health disorders, women & sexual health such as female sexual arousal disorder, female orgasmic disorder, and vaginismus and relation between infertility and cancer
- Coverage of regulatory structure, pricing, and reimbursement scenarios; marketed and pipeline (R&D) products, and clinical trials
- Identification of market drivers, restraints and other forces impacting the global market and evaluation of current market size and forecast
- Market share analysis of the key companies of the industry and coverage of their proprietary technologies, strategic alliances, and other key market strategies
- Comprehensive company profiles of the leading players of the industry, including Roche, Eli Lilly, Pfizer, AstraZeneca, Novartis, Amgen, and Merck
Table of Contents

Chapter 1 Introduction
Study Goals and Objectives
What's New in this Update?
Reasons for Doing This Study
Scope of Report
Information Sources
Methodology
Geographic Breakdown
Analyst's Credentials
BCC Custom Research
Related BCC Research Reports
Chapter 2 Summary and Highlights
Chapter 3 Overview of Technologies and Global Markets
Disease Overview and Definitions
Historical Background
Market Driving Factors and Opportunities
Aging Female Population
Government Involvement and Increased Funding
Increasing Awareness Regarding Women's Disorders and Treatments
Market Restraints
Poor Diagnosis
Availability of Alternate Treatment Options and Lifestyle Changes
Unavailability of Novel Treatments
High Treatment Cost of Osteoporosis
Opportunities
Rising Female Population in Asia-Pacific
Increased Demand for Technology Innovation
Mergers and Acquisitions
Chapter 4 Impact of COVID-19 Pandemic
Implications on Women's Health and Diagnosis
Implications on Cancer Treatment
Impact on Oncology Pharmaceuticals Market
Chapter 5 Pipeline Assessment and Analysis
Women's Health Therapeutics: Key Clinical Trial Developments
List of Drugs in Pipeline
Overview of Osteoporosis Drug Development Pipeline
Late-stage Pipeline Drugs
Chapter 6 Regulatory Structure
Overview of Regulations
U.S.
Canada
Europe
Japan
Chapter 7 Market Breakdown by Women’s Health Disorder
Introduction
Menopause-Related Diseases
Overview
Symptoms
Risk Factors
Epidemiology and Economic Burden
Diagnosis
Treatments
Market Size and Forecast
Postmenopausal Osteoporosis
Overview
Epidemiology and Economic Burden
Diagnosis
Treatments
Market Size and Forecasts
Endometriosis
Overview
Epidemiology and Economic Burden
Diagnosis
Treatments
Market Size and Forecasts
Polycystic Ovary Syndrome
Overview
Etiology
Reducing PCOS Risk
Epidemiology and Economic Burden
Disease Symptoms and Risk Factors
Diagnosis
Treatments
Market Size and Forecasts
Breast Cancer
Overview
Market Size and Forecasts
Chapter 8 Market Breakdown by Region
Introduction
North America
U.S.
Canada
Mexico
Europe
U.K.
Germany
France
Spain
Italy
Rest of Europe
Asia-Pacific
China
Japan
India
South Korea
Rest of Asia-Pacific
Rest of the World
South America
Middle East and Africa
Chapter 9 Pricing and Reimbursement
Overview of Pricing and Reimbursement
U.S.
Canada
Europe
Japan
Chapter 10 Competitive Landscape and Key Developments
Market Players and Strategies
Blockbuster Breast Cancer Pharmaceutical Brands
Patent Analysis
List of Key Patents
Key Developments
Mergers and Acquisitions
Development of Innovative Products/Novel Product Launch
Agreements, Collaborations and Partnerships
Key Products
Chapter 11 Company Profiles
ABBVIE INC.
AMGEN INC.
ASAHI KASEI
ASTRAZENECA PLC
BAYER AG
BRISTOL-MYERS SQUIBB
DAIICHI SANKYO CO. LTD.
ELI LILLY AND CO.
EISAI
F. HOFFMANN-LA ROCHE LTD.
GILEAD SCIENCES INC.
JOHNSON & JOHNSON SERVICES INC.
MERCK & CO. INC.
MERCK KGAA
NOVARTIS AG
NOVO NORDISK
PFIZER INC.
SANOFI
TAKEDA PHARMACEUTICAL CO. LTD.
Chapter 12 Conclusions: Outlook for Women’s Health Therapeutics
Major Developments to Influence Market
Therapeutic Developments
Demographic and Economic Trends
Income Growth in Emerging Markets
Future Outlook
Chapter 13 Appendix A: Glossary of Terms
Chapter 14 Appendix B: Industry and Professional Organizations
Chapter 15 Appendix C: Acronyms Used in This Report
Acronyms Used in This Report
List of Tables
Summary Table A : Global Market for Women’s Health Therapeutics and Technologies, by Disease Area, Through 2026
Summary Table B : Global Market for Women’s Health Therapeutics, by Region, Through 2026
Table 1 : Life Expectancy at Birth, Both Sexes Combined, by Region, 1990-2030 (Estimated)
Table 2 : Recent M&A Deals in the Global Market for Women’s Health Therapeutics, 2019-2021
Table 3 : Novel Breast Cancer Drug Approvals
Table 4 : Selected New Breast Cancer Drugs in Late Stages of Clinical Development
Table 5 : Pipeline Molecules, Endometriosis
Table 6 : Pipeline Molecules, Uterine Fibroids
Table 7 : Pipeline Molecules, All Other Indications
Table 8 : Pipeline Molecules, Osteoporosis
Table 9 : Elagolix Snapshot
Table 10 : Vilaprisan Snapshot
Table 11 : Evenity Snapshot
Table 12 : Relugolix Snapshot
Table 13 : Proellex Snapshot
Table 14 : Esmya Snapshot
Table 15 : TX-004HR Snapshot
Table 16 : TX-001HR Snapshot
Table 17 : Global Market for Women’s Health Therapeutics and Technologies, by Disease Area, Through 2026
Table 18 : FDA Approved Estrogen-only Medicines
Table 19 : FDA Approved Progestin-Only Medicines
Table 20 : FDA Approved Combination, Estrogen and Progestin Medicines
Table 21 : FDA Approved Combination Estrogen and Hormone Medicines
Table 22 : Vagifem (10mcg), Patent Expiration
Table 23 : Global Market for Menopause Therapeutics, by Region, Through 2026
Table 24 : Prolia/XGEVA (Denosumab) Patent Expiration
Table 25 : Global Market for Postmenopausal Osteoporosis Therapeutics, by Region, Through 2026
Table 26 : Global Market for Endometriosis Therapeutics, by Region, Through 2026
Table 27 : Commonly Prescribed Generic Drugs for the Treatment of PCOS
Table 28 : Global Market for PCOS Therapeutics, by Region, Through 2026
Table 29 : TNM Classifications of Breast Cancers
Table 30 : Global Breast Cancer Incidence, 2016-2021
Table 31 : Global Breast Cancer Incidence and Mortality, by Region, 2018
Table 32 : Types of Hormone Therapy for Breast Cancer
Table 33 : Drugs Commonly Used to Treat Breast Cancer
Table 34 : Global Market for Breast Cancer Therapeutics, by Region, Through 2026
Table 35 : Global Market for Women’s Health Therapeutics, by Region, Through 2026
Table 36 : North American Market for Women’s Health Therapeutics, by Country, Through 2026
Table 37 : North American Market for Women’s Health Therapeutics, by Disease Area Through 2026
Table 38 : U.S. Market for Women’s Health Therapeutics, by Disease Area Through 2026
Table 39 : Canadian Market for Women’s Health Therapeutics, by Disease Area, Through 2026
Table 40 : Mexican Market for Women’s Health Therapeutics, by Disease Area, Through 2026
Table 41 : European Market for Women’s Health Therapeutics, by Country, Through 2026
Table 42 : European Market for Women’s Health Therapeutics, by Disease Area, Through 2026
Table 43 : U.K. Market for Women’s Health Therapeutics, by Disease Area, Through 2026
Table 44 : German Market for Women’s Health Therapeutics, by Disease Area, Through 2026
Table 45 : French Market for Women’s Health Therapeutics, by Disease Area, Through 2026
Table 46 : Spanish Market for Women’s Health Therapeutics, by Disease Area, Through 2026
Table 47 : Italian Market for Women’s Health Therapeutics, by Disease Area, Through 2026
Table 48 : Rest of the European Market for Women’s Health Therapeutics, by Disease Area, Through 2026
Table 49 : Asia-Pacific Market for Women’s Health Therapeutics, by Disease Area, Through 2026
Table 50 : RoW Market for Women’s Health Therapeutics, by Sub-region Through 2026
Table 51 : RoW Market for Women’s Health Therapeutics, by Disease Area, Through 2026
Table 52 : South American Market for Women’s Health Therapeutics, by Disease Area, Through 2026
Table 53 : Middle East and African Market for Women’s Health Therapeutics, by Disease Area, Through 2026
Table 54 : Blockbuster Breast Cancer Pharmaceuticals, by Company Revenue, 2018-2020
Table 55 : Major Women’s Health Therapeutics Pharmaceuticals by Company Revenue, 2020
Table 56 : Global Market Shares of Women’s Health Therapeutics, by Company Revenue, 2020
Table 57 : Patent Review, 2021
Table 58 : Novel Women’s Health Therapeutic Drug Approvals, 2021
Table 59 : Selected New Women’s Health Therapeutic Drugs in Late Stages of Clinical Development
Table 60 : Marketed Products, Postmenopausal Osteoporosis
Table 61 : AbbVie: Oncology Pharmaceutical Revenue, 2018-2020
Table 62 : AbbVie Inc.: Net Revenue, 2017–2020
Table 63 : AbbVie: Oncology Pharmaceutical Product Portfolio
Table 64 : AbbVie Inc.: Marketed Products
Table 65 : AbbVie Inc.: Key Developments, 2021
Table 66 : Allergan plc: Marketed Products
Table 67 : Allergan plc: Net Revenue, 2017-2019
Table 68 : Amgen: Oncology Pharmaceutical Product Portfolio
Table 69 : Amgen: Oncology Pharmaceutical Revenue, 2018-2020
Table 70 : Amgen: Financials, 2014–2020
Table 71 : AstraZeneca: Oncology Pharmaceutical Product Portfolio
Table 72 : AstraZeneca: Oncology Pharmaceutical Revenue, 2018-2020
Table 73 : Bayer AG: Marketed Products
Table 74 : Bayer AG: Oncology Pharmaceutical Product Portfolio
Table 75 : Bayer AG: Oncology Pharmaceutical Revenue, 2018-2020
Table 76 : Bayer AG: Net Revenue, 2018-2020
Table 77 : Bristol-Myers Squibb: Oncology Pharmaceutical Product Portfolio
Table 78 : Bristol-Myers Squibb: Oncology Pharmaceutical Revenue, 2018-2020
Table 79 : Daiichi Sankyo Co. Ltd.: Marketed Products
Table 80 : Daiichi Sankyo Co. Ltd.: Net Revenue 2018-2020
Table 81 : Eli Lilly and Co.: Marketed Osteoporosis Products
Table 82 : Eli Lilly and Co.: Net Revenue, 2018-2020
Table 83 : Eli Lilly and Co.: Oncology Pharmaceutical Product Portfolio
Table 84 : Eli Lilly and Co.: Oncology Pharmaceutical Revenue, 2018-2020
Table 85 : Roche: Oncology Pharmaceutical Product Portfolio
Table 86 : Roche: Oncology Pharmaceutical Revenue, 2018-2020
Table 87 : Gilead Sciences Inc.: Oncology Pharmaceutical Product Portfolio
Table 88 : Gilead Sciences Inc.: Oncology Pharmaceutical Revenue, 2018-2020
Table 89 : Johnson & Johnson: Oncology Pharmaceutical Product Portfolio
Table 90 : Johnson & Johnson: Oncology Pharmaceutical Revenue, 2018-2020
Table 91 : Johnson & Johnson Services Inc.: Net Revenue, 2017-2020
Table 92 : Merck & Co. Inc.: Marketed Products
Table 93 : Merck & Co. Inc.: Net Revenue, 2017–2019
Table 94 : Merck & Co. Inc.: Oncology Pharmaceutical Product Portfolio
Table 95 : Merck & Co., Inc.: Oncology Pharmaceutical Revenue, 2018-2020
Table 96 : Merck KGaA Marketed Products
Table 97 : Novartis: Oncology Pharmaceutical Product Portfolio
Table 98 : Novartis: Oncology Pharmaceutical Revenue, 2018-2020
Table 99 : Novo Nordisk: Marketed Products
Table 100 : Novo Nordisk: Net Revenue, 2017–2019
Table 101 : Pfizer Inc.: Oncology Pharmaceutical Product Portfolio
Table 102 : Pfizer Inc.: Women’s Health-Marketed Products, by Indication
Table 103 : Pfizer Inc.: Oncology Pharmaceutical Revenue, 2018-2020
Table 104 : Pfizer Inc. Net Revenue, 2017–2019
Table 105 : Sanofi: Oncology Pharmaceutical Product Portfolio
Table 106 : Sanofi: Oncology Pharmaceuticals Annual Revenue, 2018-2020
Table 107 : Takeda Pharmaceutical Co, Ltd.: Oncology Pharmaceutical Product Portfolio
Table 108 : Takeda Pharmaceutical Co. Ltd.: Oncology Pharmaceutical Revenue, 2019-2021
Table 109 : New Cancer Cases in the U.S., by Age Group, 2018
Table 110 : Trends in Per Capita Real GDP Growth, by OECD Region, 2012-2016
Table 111 : Glossary of Terms Used in Women’s Health Therapeutics
Table 112 : Acronyms Used in Women’s Health Therapeutics

Report Title: Therapeutics for Women's Health: Technologies and Global Markets


Your Details
Valid Invalid number

SELECT A FORMAT

ADD TO CART BUY NOW

Related Report

2021-2026 Vietnam Virology, Bacteriology, Parasitology and Mycology Testing Database: Supplier Shares, Volume and Sales Segment Forecasts for 100 Respiratory, STD, Gastrointestinal and Other Tests

2021-2026 Vietnam Virology, Bacteriology, Parasitology and Mycology Testing Database: Supplier Shares, Volume and Sales Segment Forecasts for 100 Respiratory, STD, Gastrointestinal and Other Tests


2021-2026 Venezuela Virology, Bacteriology, Parasitology and Mycology Testing Database: Supplier Shares, Volume and Sales Segment Forecasts for 100 Respiratory, STD, Gastrointestinal and Other Tests

2021-2026 Venezuela Virology, Bacteriology, Parasitology and Mycology Testing Database: Supplier Shares, Volume and Sales Segment Forecasts for 100 Respiratory, STD, Gastrointestinal and Other Tests


2021-2026 Uruguay Virology, Bacteriology, Parasitology and Mycology Testing Database: Supplier Shares, Volume and Sales Segment Forecasts for 100 Respiratory, STD, Gastrointestinal and Other Tests

2021-2026 Uruguay Virology, Bacteriology, Parasitology and Mycology Testing Database: Supplier Shares, Volume and Sales Segment Forecasts for 100 Respiratory, STD, Gastrointestinal and Other Tests


2021-2026 United Arab Emirates Virology, Bacteriology, Parasitology and Mycology Testing Database: Supplier Shares, Volume and Sales Segment Forecasts for 100 Respiratory, STD, Gastrointestinal and Other Tests

2021-2026 United Arab Emirates Virology, Bacteriology, Parasitology and Mycology Testing Database: Supplier Shares, Volume and Sales Segment Forecasts for 100 Respiratory, STD, Gastrointestinal and Other Tests


2021-2026 Ukraine Virology, Bacteriology, Parasitology and Mycology Testing Database: Supplier Shares, Volume and Sales Segment Forecasts for 100 Respiratory, STD, Gastrointestinal and Other Tests

2021-2026 Ukraine Virology, Bacteriology, Parasitology and Mycology Testing Database: Supplier Shares, Volume and Sales Segment Forecasts for 100 Respiratory, STD, Gastrointestinal and Other Tests


2021-2026 Turkey Virology, Bacteriology, Parasitology and Mycology Testing Database: Supplier Shares, Volume and Sales Segment Forecasts for 100 Respiratory, STD, Gastrointestinal and Other Tests

2021-2026 Turkey Virology, Bacteriology, Parasitology and Mycology Testing Database: Supplier Shares, Volume and Sales Segment Forecasts for 100 Respiratory, STD, Gastrointestinal and Other Tests